Ars Pharmaceuticals Inc (SPRY)
EBITDA Growth
-33.27%
Quarterly · Period ending:
SPRY EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported-33.27%period ending
Latest reported-33.27%period ending
SPRY Quarterly EBITDA YoY % (-93.08% → -33.27%)
Year-over-year change
High-resolution chart · PNG
SPRY ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| -33.2706% | |
| -71.6578% | |
| -181.3557% | |
| -155.3985% | |
| -256.8891% | |
| -227.4001% | |
| 804.0246% | |
| -28.71% | |
| 27.9654% | |
| 31.1893% | |
| 50.3573% | |
| -125.7451% | |
| -192.4815% | |
| -107.5139% | |
| -206.051% | |
| -24.8055% | |
| -42.7849% | |
| -81.2461% | |
| 62.6783% | |
| 31.4439% | |
| 17.9405% | |
| -93.0845% |